LLY is increasing its manufacturing capacity in the United States by building four new plants. AZN's phase III study on camizestrant meets primary endpoint.
LLY is increasing its manufacturing capacity in the United States by building four new plants. AZN's phase III study on camizestrant meets primary endpoint.
Medpage Today on MSN15h
Melatonin's Anti-Cancer Potential; Prenatal PFAS and Cancer; Anti-Viral Gel for HPVA first-of-its-kind antiviral gel may offer the potential to stop papillomavirus (HPV) infection before it causes cancer. ( ...
Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said on Friday that the European Medicines Agency (EMA) endorsed ENHERTU for the ...
The committee supports approving the CFTR modulator for patients 2 years and older with at least one non-class I CFTR gene mutation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback